Efficacy, safety and immunogenicity of GSK Biologicals' HZ/su vaccine GSK1437173A in a phase IIIb, open-label, long-term follow-up study (ZOE-LTFU) of studies 110390/113077 (ZOSTER-006/022) and assessment of additional doses in older adults
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Registrational; Therapeutic Use
- Acronyms ZOSTER-049
- Sponsors GlaxoSmithKline
- 25 Jul 2017 Planned End Date changed from 25 Apr 2023 to 28 Jul 2023.
- 25 Jul 2017 Planned primary completion date changed from 25 Apr 2023 to 28 Jul 2023.
- 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.